1969250-99-4
Chemical Structure
NAB815
- CAS No.: 1969250-99-4
- Formula:C55H94N14O14
- Molecular Weight:1175.42
SMILES: O=C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@](C(NCC[C@@H](C(N[C@H](C(N1)=O)CCN)=O)NC([C@@H]([C@@H](O)C)NC([C@H]([C@H](O)C)NC([C@H](CCN)NC(CCCCCCC)=O)=O)=O)=O)=O)([H])[C@H](O)C)=O)CCN)=O)CC)=O)CC(C)C)[C@H]1CC2=CC=CC=C2
Biological Activity: NAB815 is a specific inhibitor of the Stx2a (Kd = 0.01 μM)/TLR4 interaction. NAB815 inhibits the neutrophil/Stx2a interaction (IC50 = 0.057 μg/mL). NAB815 inhibits the formation of Stx2-containing extracellular vesicles (EVs) produced by leukocytes and platelets and reduces their toxic effects in cellular (Vero cells) and animal models (CD-1 mice). NAB815 reduces bacterial loads in the kidneys, urine, and bladders of Escherichia coli-infected mice. NAB815 is useful in the study of hemolytic uremic syndrome (HUS)[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
NAB815 | NAB815 is a specific inhibitor of the Stx2a (Kd = 0.01 μM)/TLR4 interaction. NAB815 inhibits the neutrophil/Stx2a interaction (IC50 = 0.057 μg/mL). NAB815 inhibits the formation of Stx2-containing extracellular vesicles (EVs) produced by leukocytes and platelets and reduces their toxic effects in cellular (Vero cells) and animal models (CD-1 mice). NAB815 reduces bacterial loads in the kidneys, urine, and bladders of Escherichia coli-infected mice. NAB815 is useful in the study of hemolytic uremic syndrome (HUS). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Varrone E, et al. An antibiotic derivative as a new potential tool in the prevention of hemolytic uremic syndrome. iScience. 2025 Jul 7;28(8):113076. [Content Brief]
- [2]. Vaara M, et al. Polymyxin derivatives NAB739 and NAB815 are more effective than polymyxin B in murine Escherichia coli pyelonephritis. J Antimicrob Chemother. 2018 Feb 1;73(2):452-455. [Content Brief]
Keywords
